Last edited by Megis
Tuesday, May 5, 2020 | History

2 edition of plasminogen activator system in breast cancer found in the catalog.

plasminogen activator system in breast cancer

Catherine Duggan

plasminogen activator system in breast cancer

by Catherine Duggan

  • 276 Want to read
  • 6 Currently reading

Published by University College Dublin in Dublin .
Written in English

    Subjects:
  • Breast -- Cancer.,
  • Plasminogen activators.,
  • Immunocytochemistry.

  • Edition Notes

    Statementby Catherine Duggan.
    ContributionsUniversity College Dublin. Department of Biochemistry.
    The Physical Object
    Pagination317p. :
    Number of Pages317
    ID Numbers
    Open LibraryOL17231109M

    PAI‐I production by invasive breast cancers could reflect a general upregulation of the plasminogen activation system in proliferating cancer cells, as suggested by the finding that normal mammary epithelium cultures expressed PAI‐I in all cases by:   Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally identified as a blood-derived endogenous fast-acting inhibitor of by:

      Frandsen TL, Holst-Hansen C, Nielsen BS, Christensen IJ, Nyengaard JR, Carmeliet P, Brunner N: Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft by: To study interactions between disease-free survival (DFS) and four components of the plasminogen activator system: urokinase-type plasminogen activator (uPA), its two inhibitors (PAI-1 and PAI-2), and its membrane receptor conducted a retrospective study of primary breast cancer patients (median follow-up, 6 years). uPA, PAI-1, and PAI-2 were determined on cytosols and uPAR .

      Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally identified as a blood-derived endogenous fast-acting inhibitor of uPA. At concentrations found in tumor tissue, however, both PAI-1 and uPA promote tumor progression and Cited by: Plasminogen activator system in human breast cancer Plasminogen activator system in human breast cancer Sumiyoshi, K.; Serizawa, K.; Urano, T.; Takada, Y.; Takada, A.; Baba, S. We measured antigen levels of 2 kinds of plasminogen activator, tissue‐type plasminogen activator (t‐PA) and uroki‐ nase‐type plasminogen activator (UK), as well as those of their primary.


Share this book
You might also like
Biopsychology Beyond The Brain

Biopsychology Beyond The Brain

Where the coyotes howl and the bobcats prowl

Where the coyotes howl and the bobcats prowl

Helping communication in early education

Helping communication in early education

[Statue of Egyptian cat]

[Statue of Egyptian cat]

Indian education training institute

Indian education training institute

Trabue family history

Trabue family history

Kant and phenomenology

Kant and phenomenology

Reconsidering openness

Reconsidering openness

Vibration damping in multispan heat exchanger tubes

Vibration damping in multispan heat exchanger tubes

Geotectonic evolution of China / Ren Jishun ... [et al.].

Geotectonic evolution of China / Ren Jishun ... [et al.].

The dog, his world and ours

The dog, his world and ours

Permeability of concrete and its control

Permeability of concrete and its control

Engineering thermodynamics

Engineering thermodynamics

Information Industry Directory

Information Industry Directory

psycho-analysis of artistic vision and hearing

psycho-analysis of artistic vision and hearing

Plasminogen activator system in breast cancer by Catherine Duggan Download PDF EPUB FB2

The plasminogen activator (PA) system is a key regulator of the tumor microenvironment, and is heavily implicated in the metastatic process in breast and other common cancers.

It is involved in tumor recruitment of inflammatory cells, tumor cell growth and survival, angiogenesis, and tumor invasion and migration [39,40].Cited by: 1. Ross W. Stephens, Nils Brünner, Fritz Jänicke and Manfred Schmitt, The urokinase plasminogen activator system as a target for prognostic studies in breast cancer, Breast Cancer Research and Treatment, /A, 52,(), ().Cited by: Biology of the uPA System.

The uPA system is a conversion system from plasminogen into plasmin, which plays important physiological roles. It also plays a key role in cancer invasion and metastasis dissemination by allowing malignant cells to invade the tumor site locally and spread to distant by: 5.

The uPA system is a conversion system from plasminogen into plasmin, which plays important physiological roles. It also plays a key role in cancer invasion and metastasis dissemination by allowing malignant cells to invade the tumor site locally and spread to distant sites.

7,8 This system includes the serine protease, uPA, membrane-linked receptor uPAR, and two serpin inhibitors, PAI-1 Cited by: 5. gen activator system, urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1), have been found to play possibly a key role in individualizing breast cancer treatment.

The predictive value of the combinational use of these two biological markers for discriminating the. One proteolytic system involved in these processes is the urokinase-type plasminogen activator (uPA) system, which consists of uPA, uPA receptor (uPAR) and uPA inhibitors 1 and 2 (PAI-1 and PAI-2).

In the past two decades, study of the uPA system in human breast cancer Cited by: Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

J Clin Cited by: tors plasminogen activator inhibitor types 1 and 2 (PAI-1 and PAI-2, respectively), have been established as prognostic factors in primary breast cancer by various research groups (reviewed in Refs.

1, 4, and 5). In primary breast cancer, uPA and PAI-1 reached level-I evidence for their prognostic impact (6, 7), according to proposed guidelines Cited by: The urokinase plasminogen activator system in breast cancer invasion and metastasis Linlin Tanga, Xiuzhen Hana,*,b aDepartment b ofPharmacology, School Pharmaceutical Sciences, ShandongUniversity, 44, West Wenhua Road, Jinan, ProvinceChina Key.

The prognostic value of components of the urokinase-type plasminogen activator (uPA) system, its receptor uPAR (CD87), and plasminogen activator inhibitors PAI-1 and PAI-2 is well established.

We studied the predictive value of these proteolytic factors by evaluating the association of their tumor expression level and the efficacy of tamoxifen therapy in patients with recurrent breast by: The plasminogen activator/plasmin system.

The effects of complete ablation of plasminogen activation in cancer was studied by inoculation of a metastatic Lewis lung carcinoma expressing high. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.

The urokinase plasminogen activator system, which is a serine protease family include urokinase-type plasminogen activator (uPA), the uPA receptor and plasminogen activator inhibitors (PAIs).

uPA catalyzes the transformation of plasminogen to its active form plasmin, which is able to degrade the extracellular matrix (ECM) and basement membranes, directly or indirectly through activating pro Cited by: Plasminogen activators are serine proteases that catalyze the activation of plasmin via proteolytic cleavage of its zymogen form plasminogen.

Plasmin is an important factor in fibrinolysis, the breakdown of fibrin polymers formed during blood clotting. There are two main plasminogen activators: urokinase (uPA) and tissue plasminogen activator (tPA).

Substantial evidence exists which implicates the urokinase plasminogen activator system [urokinase plasminogen activator (uPA), urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1)] in the neo-vascularization, invasion and metastasis of many solid tumors.

Clinical studies have demonstrated an association between high levels of Cited by: RW Stephens, N Brünner, F Jänicke, etal: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer Breast Cancer Res Treat 99 –Crossref, Medline, Google Scholar: by: 7.

The urokinase plasminogen activator system, which is a serine protease family include urokinase-type plasminogen activator (uPA), the uPA receptor and plasminogen activator inhibitors (PAIs).

uPA. We measured antigen levels of 2 kinds of plasminogen activator, tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (UK), as well as those of their primary inhibitors, type-I plasminogen activator inhibitor (PAI-1) and type-2 plasminogen activator inhibitor (PAI-2), in tissue extracts from benign and malignant breast by: breast cancer.

This study aimed to correlate CTCs, blood coagulation and the urokinase plasminogen activator (uPA) sys-tem in primary breast cancer (PBC) patients. This prospective study included PBC patients treated by primary surgery. PURPOSE: To study interactions between disease-free survival (DFS) and four components of the plasminogen activator system: urokinase-type plasminogen activator (uPA), its two inhibitors (PAI-1 and PAI-2), and its membrane receptor uPAR.

PATIENTS AND METHODS: We conducted a retrospective study of primary breast cancer patients (median follow-up, 6 years). Cited by:. A form of tissue plasminogen activator that is made in the laboratory.

It helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. It is also being studied in the treatment of cancer. It is a type of systemic thrombolytic agent. Also called Activase, Alteplase, and r-tPA.The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro Rosanna Paciucci, Montserrat Tora`,Vı´ctor M Dı´az and Francisco X Real Unitat de Biologia Cellular i Molecular, Institut Municipal d’Investigacio´ Me`dica, Barcelona, Spain Plasminogen activators (PAs) play an important role inCited by: Urokinase – type Plasminogen Activator System in Human Breast Cancer Reyadh Salim Al-Jubouri1*, Faeza Aftan Al-Rawi2, Ali Hussien Al-Khafaji3 1Department of Biology, College of Science, Tikrit University, Salah Al-Din, Iraq.

2Ibn-Sina College of Medicine, Al-Iraqia University, Baghdad, Iraq, 3Central Public Health Laboratory, Ministry of Health.